![1]()
News
Oral step-down therapy for infective endocarditis
December 13, 2021
What is oral step-down therapy’s relative clinical effectiveness, compared with prolonged IV antibiotics for infective endocarditis (IE)?
![1]()
News
New data on rare myocarditis after COVID-19 vaccination
December 8, 2021
Most adolescents and young adults recover quickly from the rare complication of myocarditis following mRNA COVID-19 vaccination, a new study shows.
![1]()
News
Apixaban outmatches rivaroxaban for VTE in study
December 6, 2021
These real-world findings may guide selection of initial anticoagulant therapy, according to authors of the paper.
![1]()
News
Care via video teleconferencing can be as effective as in-person for some conditions
December 6, 2021
Video teleconferencing works best for monitoring patients with chronic conditions, according to the author of a new paper.
![1]()
News
No serious CV risks for elderly after Pfizer COVID-19 vaccine
December 2, 2021
A French study adds to other evidence that the Pfizer mRNA COVID-19 vaccine does not increase the risk for serious cardiovascular adverse events in elderly individuals.
![1]()
News
SGLT2 inhibitor use tied to fewer atrial arrhythmias
December 2, 2021
A prospective study of nearly 14,000 patients who received an implantable cardiac device suggests that SGLT2-inhibitor treatment cuts atrial arrhythmias.
![1]()
News
Bedside frailty assessment can determine when CPR will be nonbeneficial
December 1, 2021
How does frailty impact survival after inpatient cardiac arrest in older adults?
![1]()
News
Optimizing perioperative cardiac risk assessment and management for noncardiac surgery
November 30, 2021
What is the sum of evidence supporting perioperative cardiac risk assessment and risk reduction?
News
Predicting cardiac shock mortality in the ICU
November 23, 2021
Including biventricular dysfunction as assessed using transthoracic echocardiography improves clinical risk stratification.
News
Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved
November 19, 2021
Study shows empagliflozin led to a consistent, significant relative risk reduction compared with placebo in the primary endpoint.
